CIPLA SHARES
Cipla’s US recovery, biosimilar pipeline key to future growth prospects
Cipla's September-quarter earnings suffered due to a high base in its US business. The company reported sequential growth driven by its strong India business and branded prescription therapies. Recent approvals for respiratory products and a growing biosimilar pipeline bolster Cipla's optimism for future growth. Despite declining operating margins, the firm anticipates improvements supported by product launches. Cipla remains focused on evaluating inorganic opportunities to enhance its specialty portfolio.
Cipla sets sights on first-wave gains from rollout of Keytruda Biosimilar
Cipla has partnered with Qilu Pharmaceutical to commercialize a biosimilar of Keytruda, which is a major cancer treatment. The patent for this drug is expected to expire around 2029, allowing for potential market entry. Cipla anticipates capturing a significant share of this lucrative market segment after the launch. Additionally, the company reported a 35% decline in consolidated net profit in the September quarter.
Cipla Q2 net profit falls 35% to Rs 878 crore, revenue dips 2%
Cipla reported a 35% year-on-year decline in second-quarter net profit to Rs 878 crore, with revenue and EBITDA also falling amid weaker North American sales. India revenue grew 12%, while US regulatory approval and a biosimilar partnership supported its product pipeline.
Cipla expects US business to draw support from upcoming product pipeline
Cipla reported a significant decline in its consolidated net profit for the second quarter of FY27. The company's North American revenue fell by 19% due to increased competition impacting sales of generic Revlimid. However, Cipla anticipates that its upcoming product pipeline will support performance in North America. In India, domestic revenue rose, providing some resilience amidst challenges in the US market.
Cipla Q2 Results: Profit falls 35% YoY to Rs 878 crore; revenue slips 2%
Cipla reported a 35% drop in consolidated net profit for Q2FY27, which stood at Rs 878 crore. The company also experienced a 2.4% year-on-year decline in revenue from operations, totaling Rs 7,404 crore. Additionally, a significant 26.7% decrease in EBITDA resulted in a lower margin of 18.7%. Nonetheless, Cipla's One India division demonstrated growth across various segments, while the company aims to enhance productivity and innovate its product offerings.
Stocks in news: Paytm, Tata Consumer, Dalmia Bharat, REC and DCM Shriram
Indian equity markets showed recovery with a rise in NSE Nifty 50, ending a four-session losing streak. Several companies reported their September-quarter earnings, highlighting varying financial performances. Paytm experienced significant profit growth, while Dalmia Bharat reported a net loss due to an exceptional charge. Defence stocks are also in focus following government procurement approvals. Investors continue to track earnings reports and related developments in the market.
- Go To Page 1
Cipla subsidiary clears USFDA inspection with zero observations
Cipla on Friday said a routine US Food and Drug Administration (USFDA) inspection at its wholly owned subsidiary InvaGen Pharmaceuticals' manufacturing facility in Hauppauge, Long Island, New York.
Zydus moves closer to US market for Keytruda biosimilar as FDA accepts application
Zydus Lifesciences has received acceptance for its application regarding the biosimilar of Keytruda, which is a major cancer drug. The USFDA is expected to complete its review process by the third quarter of 2027. This biosimilar, named FYB206, was developed without a comparative Phase III efficacy trial. Zydus aims to make effective treatments more accessible in the oncology field in North America.
When nothing is cheap, winners may come from any corner: 19 stocks with downside to upside potential of -28% to plus 22%
Because each pharma company took a different road, they no longer rise and fall together. Where any one of them stands in 10 years depends on what it chose in the last five or six. So, one name can do wonderfully while the one sitting next to it does very little. Stock Reports Plus, powered by Refinitiv, is a comprehensive report that evaluates five key components of 4,000+ listed stocks – earnings, fundamentals, relative valuation, risk, and price momentum – to generate standardised scores. The simple average of the above-mentioned five component ratings is normally distributed to reach an average score.
Nifty 50 companies likely to log strong double-digit growth in Q2
Revenue and net profit of Nifty 50 companies are projected to grow by nearly 20% year-on-year. Analysts note that performance is driven by sectors like automobiles, banking, and oil. Operating margins, however, might contract slightly due to input cost pressures and inflation. Key sectors show varied conditions, balancing strong demand against potential challenges. Overall, medium to long-term outlook remains optimistic, despite some near-term volatility.
Short-term headwind? Yes. But the structure stays intact: 5 large-cap stocks with upside potential of up to 19%
Wise men on the street will tell you it is foolish to try and time the market. And attempting to do so in the midst of a raging war is probably even more foolhardy. But even in these uncertain times, there is something that can be said with certainty: This war will also end. So, think beyond war, even as it rages on. Think of the structural stories that are changing some sectors.
Stocks in news: Groww, Tata Motors PV, Cipla, Varun Beverages and Axis Bank
The Indian equity market experienced a positive turnaround on Tuesday, August 25, highlighted by the Nifty 50 making a robust recovery. Anticipation builds for Wednesday as Groww gears up for a significant block deal, while Cipla faces new USFDA inspectional observations. In other news, Tata Motors Passenger Vehicles is set to enhance its electric vehicle offerings through a collaboration with Tata Communications for 5G technology.
Cipla Q1 Results: Cons profit drops 39% YoY to Rs 789 crore; revenue rises marginally
Cipla Q1 Results: Pharma major Cipla reported a 39% year-on-year decline in Q1FY27 consolidated net profit to Rs 789 crore, mainly due to a high base, while revenue from operations rose a modest 2.3% to Rs 7,119 crore. The company's EBITDA also declined, with margins contracting sharply compared with the year-ago quarter.
Cipla shares rally 8% despite 55% YoY slump in Q4 profit. Why Citi, Nuvama, other brokerages hiked target
Cipla shares surged on Thursday, extending gains to nearly 11% in two sessions, after several brokerages turned bullish on the stock despite a weak Q4 performance. The stock hit an intraday high of Rs 1,432.10 as investors focused on future growth prospects over near-term earnings pressure.
Cipla shares slide 5% after temporary halt in key drug manufacturing
Cipla shares fell sharply on Friday after a halt in Lanreotide Injection production due to USFDA observations at its Greek partner. Supply is expected to resume in H1 FY27. The stock trades near oversold levels, with bearish technical indicators, amid investor concern over the limited availability of a top US product.
Cipla shares in focus after deal to acquire Inzpera Healthsciences for Rs 111 crore
Cipla shares: Cipla has agreed to acquire a 100% stake in Inzpera Healthsciences, making it a wholly owned subsidiary, as part of its strategy to strengthen its presence in the paediatric and wellness segment.
Cipla Q2 Results: Net profit grows 4% YoY to Rs 1,351 crore; revenue rises 8%
Cipla Q2 Results: Cipla reported a 4% YoY growth in net profit to Rs 1,351 crore and an 8% rise in revenue to Rs 7,589 crore. The company saw strong performance in its India and North America businesses, with key products like Foracort and Albuterol leading.
Cipla shares rally 6% in 2 days as Q1 results impress; brokerages raise target up to Rs 1,875
Cipla shares: Following the earnings announcement, several brokerage firms revised their target price for the stock, with some estimates reaching as high as Rs 1,875 per share, indicating potential for further upside.
Cipla shares in focus after Goa facility receives form 483 with one observation from USFDA
Cipla share price has risen by 10% over the past 12 months and 64% over the last three years. The company's current market capitalization is Rs 1,16,772 crore. The consensus recommendation from 37 analysts for the stock is a 'Buy'.
Cipla shares rise over 2% as Kotak forecasts better days ahead, upgrades rating to ‘buy’
Cipla shares rose by 2.4% to Rs 1,483.40 on Tuesday after Kotak Institutional Equities upgraded the stock from "add" to "buy," with a target price of Rs 1,725. This suggests a potential upside of over 16% from the current levels.
Cipla shares in focus as promoters Samina and Rumana Hamied offload 1.72% stake for Rs 2,111 crore
Cipla shares are in focus today after Samina Hamied and Rumana Hamied, promoters of the pharmaceutical company, exited by selling their 1.72% stake for Rs 2,111 crore through open market transactions. Investors, including the Singapore government, Societe Generale, Abu Dhabi Investment Authority, BNP Paribas, BofA Securities, Citigroup, Morgan Stanley, Goldman Sachs, Norges Bank, UBS, and Copthall Mauritius, bought stakes in Cipla.
Cipla shares in focus on Rs 2,000 crore likely block deal
Cipla's shares are likely to attract attention on Monday as the company's promoters may sell up to a 1.72% stake through block deals. The offer price is expected to be set at Rs 1,442 per share, with the total block size estimated at Rs 2,000 crore.
Cipla shares zoom nearly 10% as USFDA classifies Goa facility for voluntary action
Cipla's shares surged 9.8% after the USFDA classified its Goa facility inspection as Voluntary Action Indicated (VAI), allowing for critical drug launches, including the Abraxane generic. Over the past year, the stock has risen 28.26%, with a 23% increase this year, despite a recent 7% decline.
Cipla stock in focus after Q2 PAT beats estimates. Should you buy, sell or hold?
Cipla's shares are in focus as the company reported a 15% YoY increase in consolidated net profit to Rs 1,303 crore for Q2 2024. Revenue rose 6% to Rs 7,051 crore, with EBITDA growing 12%. Despite mixed outlooks from analysts, including BofA's 'Underperform' and UBS's 'Buy' rating, concerns about market challenges and product launch delays persist.
Cipla promoters mull stake sale to top PE firms Blackstone, Baring Asia: Report
However, the company has issued a clarification, saying that "the company is not aware of any event that requires disclosure under Listing Regulations. The company will make appropriate disclosure in compliance with the listing regulations as and when any such requirement arises."
Cipla skids 4% on Jan-Mar earnings miss
The total revenue from operations was Rs 5,260.33 crore, up 14.19 per cent from Rs 4,606.45 crore the company reported in the year-ago quarter.
Dispute settlement gives this stock an edge over peers in pharma pack
Kunal Dhamesha of Emkay Global raised his price target for the stock to Rs 1,000 and sees potential gain of Rs 45 per share from the settlement.
Analysts give a thumbs up to Cipla’s Q2 report card, see 30% upside in the stock
Jefferies was the most optimistic as it maintained its buy rating on the stock, and raised the target price to Rs 1,024 from Rs 914 earlier.
Q2 takeaways: Will Cipla’s earnings drive the stock further?
Its India business grew by 17 per cent YoY with strong growth across the three businesses and continued servicing of patients with Covid-19 portfolio.
Load More
